Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397773 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.
J Allergy Clin Immunol Pract
September 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado, USA. Electronic address:
Background: Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.
Objective: The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (hf-SCIg) for inflammatory myositis: a multicenter retrospective real-world observational study.
Eur J Intern Med
August 2025
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia. Electronic address:
Background: Subcutaneous immunoglobulin (SCIg) is a promising alternative to intravenous Ig (IVIg) for the treatment of idiopathic inflammatory myositis (IIM), thanks to its more favorable safety profile, reduced costs, and lower impact on patients' quality of life. We assessed the short- and long-term effectiveness and safety of recombinant human hyaluronidase-facilitated SCIg (hf-SCIg) in patients with IIM treated at different referral centers in Italy.
Methods: A multicenter, retrospective, real-life cohort study was conducted on consecutive adult patients diagnosed with IIM according to the EULAR/ACR criteria, treated with hf-SCIg for remission induction or maintenance.
The Role of Dupilumab in Atopic Dermatitis-Like Graft-Versus-Host Disease.
Cureus
July 2025
Pediatric Allergology Unit, Centro Materno Infantil do Norte, Unidade Local de Saúde de Santo António, Porto, PRT.
Atopic dermatitis-like graft-versus-host disease (AD-like GVHD) is a rare but challenging complication following hematopoietic stem cell transplantation (HSCT), mimicking features of atopic dermatitis (AD) and often requiring prolonged immunosuppression. We report the case of a 14-year-old girl with a history of mild AD and post-HSCT GVHD involving skin and the gastrointestinal tract, presenting with severe pruritus, extensive eczema, and significant impact on quality of life. Standard treatment with corticosteroids and immunosuppressants yielded suboptimal results and notable side effects, including growth retardation.
View Article and Find Full Text PDFComparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study.
J Neurol
July 2025
Department of Internal Medicine, University Hospital Charles Nicolle, 76 000, Rouen, France.
Introduction: Neurosarcoidosis is a granulomatous disease affecting 10% of patients with sarcoidosis. In lack of standardized guidelines, various therapeutic strategies exist. Beyond corticosteroids, cyclophosphamide, infliximab, or methotrexate are available options.
View Article and Find Full Text PDF